Postmenapozal osteoporozlu hastalarda oral ve parenteral bifosfonatların etkinliğinin Karşılaştırılması: Tek merkezli retrospektif klinik çalışma

Abstract

Listen

Translate article

Aim: The aim of the study is to compare the efficacy of oral and parenteral bisphosphonates used in the treatment of postmenopausal osteoporosis.
 Material and Methods: Patients older than 50 years who were diagnosed with postmenopausal OP and treated with oral or parenteral bisphosphonate between 2016 and 2019 were included in the study. The patients were grouped by treatment; 80 patients receiving oral bisphosphonate and 80 patients receiving parenteral bisphosphonate were divided into two groups as group ‘O’ and group ‘P’, respectively. The results of the second-year treatment of 160 patients, who were treated regularly and could be followed-up for at least 2 years, were evaluated and compared. Results: According to the pre-treatment state in both groups; vertebral and femoral bone mineral density (BMD) and T-scores showed significant improvement. The mean improvement in vertebral and femoral T-scores and femoral BMD values was better in group ‘P’ with a statistically significant difference. In the oral bisphosphonate group, there was a statistically significant difference between the groups in favor of alendronate in the femoral T-score, while, in the parenteral bisphosphonate group, the improvement in the vertebral and femoral T-score was better in the zoledronate subgroup and statistically significant.
 Conclusion: This study concluded that oral and parenteral bisphosphonates are effective in the treatment of postmenopausal OP. Nevertheless, parenteral bisphosphonates were found to be more effective in terms of mean improvement in vertebral and femoral T-scores and femoral BMD.